Abeona’s first-ever U.S. Biologics License Application (BLA) submission completed in September 2023 FDA decision on priority review and acceptance of…
Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple…
Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash (an…
- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq:…
– New analysis on serum leptin levels among patients in the Target-HTN Phase 2 trial adds to emerging evidence of…
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct…
Innovative new treatment option for patients with uncontrolled hypertension now available in the United StatesPALO ALTO, Calif.--(BUSINESS WIRE)--Recor Medical, Inc.…
Phase 2b SYMMETRY 36-week data, including new subgroup analysis, showed that EFX is active in patients with advanced cirrhosis and…
Leiden, The Netherlands, November 10, 2023: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that it…
Data release to follow late-breaker poster presentation at AASLD The Liver Meeting® 2023EDISON, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) --…